Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
NCT ID: NCT00954811
Last Updated: 2010-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
40 participants
INTERVENTIONAL
2005-09-30
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GnRH Agonist for Luteal Phase Support.
NCT05484193
Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS
NCT02827656
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
NCT06150703
Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates
NCT05838105
Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
NCT01093443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCG for ovulation triggering and luteal progesterone
conventional triggering with HCG and conventional luteal support with progesterone
progesterone 600mg
luteal support
Agonist triggering and rec-LH luteal support plus progesterone
new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
300IU rec-LH
luteal alternate doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
300IU rec-LH
luteal alternate doses
progesterone 600mg
luteal support
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* single blastocystET,
* FSH \< 12
Exclusion Criteria
* 3 and 4,
* pco,
* frozen sperm
20 Years
36 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Serono International SA
INDUSTRY
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Centre for Reproductive Medicine,UZ Brussel
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Devroey
Role: STUDY_CHAIR
Professor or OB-GYN
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Reproductive Medicine, UZ Brussel
Brussels, Jette, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
recombinant LH 1505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.